Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  SK Biopharmaceuticals Co., Ltd.    A326030   KR7326030004

SK BIOPHARMACEUTICALS CO., LTD.

(A326030)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
11/24/2020 11/25/2020 11/26/2020 11/27/2020 11/30/2020 Date
174000 174500 179500 188500 187500 Last
411011 746911 440229 911660 2393133 Volume
+2.05% +0.29% +2.87% +5.01% -0.53% Change
Financials
Sales 2020 50,9 B 0,05 B 0,05 B
Net income 2020 -208 B -0,19 B -0,19 B
Net cash position 2020 424 B 0,38 B 0,38 B
P/E ratio 2020 -99,0x
Yield 2020 -
Sales 2021 242 B 0,22 B 0,22 B
Net income 2021 -85,0 B -0,08 B -0,08 B
Net cash position 2021 297 B 0,27 B 0,27 B
P/E ratio 2021 -386x
Yield 2021 -
Capitalization 14 684 B 13 253 M 13 259 M
EV / Sales 2020 288 653x
EV / Sales 2021 60 640x
Nbr of Employees -
Free-Float 21,9%
More Financials
Company
SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business. 
Sector
Pharmaceuticals
Calendar
-
More about the company
All news about SK BIOPHARMACEUTICALS CO., LTD.
11/27Vaccine developer SK Bioscience targets IPO in first half of 2021
RE
11/02SK Biopharmaceuticals and LifeSci Venture Partners Forge Ties for Open Innova..
AQ
10/16BTS manager Big Hit takes a beating as stock loses more than a fifth
RE
10/14SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenob..
AQ
10/14Ono Enters into License Agreement on Cenobamate, an Antiepileptic Drug with S..
AQ
09/25Fans of boy band BTS join swarm of Ants chasing South Korea's hit IPO
RE
More news
News in other languages on SK BIOPHARMACEUTICALS CO., LTD.

- No features available -

More news
Chart SK BIOPHARMACEUTICALS CO., LTD.
Duration : Period :
SK Biopharmaceuticals Co., Ltd. Technical Analysis Chart | A326030 | KR7326030004 | MarketScreener
Technical analysis trends SK BIOPHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 116 000,00 KRW
Last Close Price 187 500,00 KRW
Spread / Highest target -9,33%
Spread / Average Target -38,1%
Spread / Lowest Target -53,6%
EPS Revisions
Managers
NameTitle
Jeong-Woo Jo President, Chief Executive Officer & Director
Geun-Joo Hwang Non-Executive Director
Young-Ju Bang Independent Director
Hae-Young Ahn Independent Director
Min-Seop Song Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SK BIOPHARMACEUTICALS CO., LTD.0.00%13 253
MERCK KGAA27.05%69 553
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD90.24%19 173
KYOWA KIRIN CO., LTD.10.18%14 594
BETTA PHARMACEUTICALS CO., LTD.38.95%5 594
YUHAN CORPORATION36.15%3 641